Orion - Company Announcement

Composition of the Nomination Committee of Orion Corporation

ORION CORPORATION      STOCK EXCHANGE RELEASE 7 SEPTEMBER 2016 at 6.30 p.m.
EEST


Composition of the Nomination Committee of Orion Corporation


The Board of Directors of Orion Corporation has elected the following persons to
the Nomination Committee of the company:

  * Kari Jussi Aho
  * Erkki Etola
  * Matti Kavetvuo
  * Timo Maasilta
  * Timo Ritakallio
  * Seppo Salonen
  * Hannu Syrjänen

Matti Kavetvuo was elected Chairman of the Committee.


The Committee prepares and presents a recommendation to the Board of Directors
for the proposal to the Annual General Meeting concerning the composition of the
Board.


The essentials of the working order of the Nomination Committee and a
description of the election process of its members are provided at
http://www.orion.fi/en/Orion-group/corporate-governance/board-of-
directors/board-committees/, a page in the Corporate Governance section of the
Orion Group internet website.



Orion Corporation



 Timo Lappalainen    Olli Huotari
 President and CEO   SVP, Corporate Functions



Contact person:
Timo Lappalainen, President and CEO
tel. +358 10 426 3692

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02101 Espoo, Finland
Homepage: www.orion.fi


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. The core therapy areas of Orion's pharmaceutical R&D are
central nervous system (CNS) disorders, oncology and respiratory for which Orion
developes inhaled Easyhaler® pulmonary drugs.

Orion's net sales in 2015 amounted to EUR 1,016 million and the company had
about 3,400 employees. Orion's A and B shares are listed on Nasdaq Helsinki.


[]